Scabies Disease: Mites, Outbreaks and Global Burden
Updated
Scabies disease is a skin infestation by the mite Sarcoptes scabiei var. hominis, and the World Health Organization (WHO) estimates that it affects more than 200 million people at any one time. For one patient it means weeks of itch and a burrowing rash; for a community it is a public health problem. Since 2017 WHO has listed scabies among the neglected tropical diseases, because in crowded, resource-poor tropical settings between 5% and 50% of children can be infested, and the skin sores that follow can lead to sepsis and kidney disease. In high-income countries the disease shows up as outbreaks in care homes, hospitals and prisons, often started by an unrecognized case of crusted scabies. This guide follows the mite's life cycle, the global burden, crusted scabies, institutional outbreaks, complications and mass drug administration, using WHO, CDC and UKHSA guidance and peer-reviewed trials.
In clinical work, scabies questions rarely stop at one prescription. A ward nurse needs to know which contacts to treat, a resident wants the threshold for treating a whole community, and an infection control lead has to decide when an outbreak is over. AskMed is a medical question app for doctors, nurses, pharmacists, medical students and researchers that searches guidelines, journals and public health guidance before it answers, and links every statement to its source. Ask it how UKHSA defines a scabies outbreak in a care home and how long surveillance should run, and the answer cites the guidance itself.
Ask AskMed how UKHSA defines a scabies outbreak and when it can be declared over:
- CauseSarcoptes scabiei var. hominis, spread by close skin-to-skin contact
- Global burdenMore than 200 million people at any time; a WHO neglected tropical disease since 2017
- Severe formCrusted (Norwegian) scabies, with up to two million mites and eggs (CDC)
- Public health toolsOutbreak control in institutions; mass drug administration where prevalence is 10% or more
What is the life cycle of the scabies mite?
The scabies mite, Sarcoptes scabiei var. hominis, completes its whole life cycle on human skin, which is why the disease passes from person to person through close contact. The CDC parasitology reference DPDx describes four stages: egg, larva, nymph and adult. A fertilized female digs a winding burrow in the top layer of the skin and lays 2 to 3 eggs a day as she lengthens it, for the rest of her life of 1 to 2 months. The oval eggs, 0.10 to 0.15 mm long, hatch in 3 to 4 days; the six-legged larvae moult into eight-legged nymphs and then adults, and WHO says the whole development from egg to adult takes 1 to 2 weeks. Mating happens only once and leaves the female fertile for life. Even under the most favorable conditions only about 10% of her eggs become adult mites, and WHO notes that most people with common scabies carry just 10 to 15 mites. Adult females measure 0.30 to 0.45 mm.
- Transfer: a fertilized female moves to a new person during close skin-to-skin contact.
- Burrow and eggs: she burrows into the top layer of the skin and lays 2 to 3 eggs a day for 1 to 2 months.
- Larva: eggs hatch in 3 to 4 days; six-legged larvae make shallow moulting pouches.
- Nymph: larvae moult into eight-legged nymphs, which moult again into adults.
- Adult: egg to adult takes 1 to 2 weeks; mating happens once and each fertilized female starts her own burrow.
The timing explains much of the disease's behavior in groups. Itch and rash are an allergic reaction to mite proteins and faeces in the burrow, and WHO says they usually begin 4 to 6 weeks after infestation; CDC DPDx says a first infestation may cause no symptoms for up to two months, while the person can still pass mites on. Someone who has had scabies before is already sensitized and usually reacts within 1 to 4 days. Transmission happens mainly through the transfer of fertilized females during skin-to-skin contact, and only occasionally through bedding or clothing. Away from human skin, WHO says scabies mites usually die after 2 to 3 days.
Why is scabies a neglected tropical disease?
WHO added scabies and other ectoparasites to its list of neglected tropical diseases (NTDs) in 2017, in response to requests from Member States and the advice of its Strategic and Technical Advisory Group for NTDs, and the size of the problem explains why. The WHO fact sheet estimates that scabies affects more than 200 million people at any time and more than 400 million people cumulatively every year. The disease is found in every country but is most common in hot, densely populated, resource-poor tropical settings, where prevalence among children varies from 5% up to 50% and recurrent infestations are common. A systematic review of 48 community studies by Romani and colleagues (Lancet Infectious Diseases, 2015) found prevalence ranging from 0.2% to 71.4%, highest in the Pacific and Latin America and much higher in children than in adolescents and adults. The WHO road map for neglected tropical diseases 2021–2030 puts the burden at about 4.5 million disability-adjusted life years (DALYs) in 2017.
The Global Burden of Disease 2015 analysis by Karimkhani and colleagues (Lancet Infectious Diseases, 2017) found that scabies caused 0.21% of the DALYs from all conditions it studied. East Asia, southeast Asia, Oceania, tropical Latin America and south Asia carried the heaviest burden, the five countries with the highest burden were Indonesia, China, Timor-Leste, Vanuatu and Fiji, and the burden peaked in children, adolescents and older people. That analysis assumed no deaths from scabies, so its figures count itch, pain and disfigurement, not the bacterial complications described below. The road map itself says accurate incidence and prevalence data are not available.
WHO targets for 2030
Scabies is a disease targeted for control, not elimination. The road map sets two indicators: the number of countries that have incorporated scabies management in their universal health coverage package of care, from none in 2020 to all 194 by 2030 (milestones of 25 by 2023 and 50 by 2025), and the number of countries using mass drug administration in all endemic districts, from none to 25 by 2030. WHO counts an area as endemic for this purpose when scabies prevalence is 10% or more, and it recommends that scabies control sit within an integrated approach to the skin NTDs.
What is crusted (Norwegian) scabies and who gets it?
Crusted scabies, formerly called Norwegian scabies, is a severe form of the disease in which the immune response fails to control the mite, so the mite population grows into the thousands or millions instead of the 10 to 15 seen in common scabies. The CDC clinical overview says one patient may carry up to two million mites and eggs, and describes hyperkeratotic plaques that may be fissured, sometimes with redness, while the classic rash may be missing and itch may be mild or absent. CDC lists the people most at risk as older adults, people who are immunocompromised, such as those living with HIV, and people with conditions that stop them feeling itch or scratching, including spinal cord injury, paralysis, loss of sensation and severe mental or behavioral health conditions. UKHSA adds immunosuppressive therapy such as corticosteroids. WHO calls crusted scabies life threatening, and CDC says it needs prompt, aggressive treatment to prevent sepsis and outbreaks.
Two features make crusted scabies the usual engine of outbreaks. First, skin scales full of mites are shed onto bedding, clothing, furniture and floors, so WHO notes that spread through personal items, unlikely with common scabies, may matter for crusted scabies. Second, because itch is slight, the diagnosis is easily missed, and CDC states that unrecognized crusted scabies is frequently the source of institutional scabies outbreaks. WHO says these patients are highly infectious, are a source of reinfection for the wider community and need intense treatment with both topical and oral medicines.
Infection control advice differs between agencies. CDC recommends contact precautions with gowns, gloves and shoe covers, maintained until skin scrapings from the patient are negative. UKHSA does not recommend isolating people with crusted scabies; it relies on standard infection control with gloves and aprons to avoid skin-to-skin contact, longer daily vacuuming, a deep clean after treatment and specialist input on when the person is no longer infectious.
Why do scabies outbreaks happen in care homes, hospitals and prisons?
Scabies outbreaks happen in care homes, hospitals and prisons because the disease spreads through prolonged skin-to-skin contact, and those settings combine close living, hands-on care and residents in whom the infestation is easy to miss. WHO lists closed institutional settings such as hospitals, boarding schools and long-term care facilities, along with refugee and displaced-person camps, as places where outbreaks occur and can be extended and difficult to control. CDC names nursing homes and extended-care facilities, jails and prisons, childcare facilities and homeless shelters. UKHSA notes that two-thirds of residents in care homes for older adults live with dementia or other cognitive impairment, that older residents may have a rash hidden under clothing or no symptoms at all, and so recommends a careful examination with clothing removed. It describes prisons as transient, communal and crowded. Delay is built in, because a first infestation can stay silent for weeks while the person spreads mites.
The first sign of an outbreak is often a member of staff. CDC notes that scabies in institutions is often recognized only after staff are affected, and that a staff member with symptoms, especially one who has had scabies before, may point to undetected scabies in a patient or resident. A 2020 review in the Journal of the American Academy of Dermatology (Thomas and colleagues) makes the same point at a larger scale: in high-income countries, delays in diagnosis can lead to institutional outbreaks, while in low- and middle-income countries poor access to care leads to undertreatment and long-term complications.
How are institutional scabies outbreaks managed?
Institutional scabies outbreaks are managed by confirming the diagnosis early, tracing every contact, treating cases and contacts together, and watching long enough to be sure transmission has stopped. UKHSA defines an outbreak as 2 or more epidemiologically linked cases of scabies within an 8-week period in one setting, and the local health protection team may set up an incident management team to oversee the response. CDC advises notifying the local health department when there are multiple cases, confirming suspected cases with skin scrapings examined by someone trained to identify mites, and recording each case's room, roommates and the staff who gave hands-on care before mapping cases by building, floor, wing and date of onset. Both agencies treat contacts alongside cases. UKHSA asks that all contacts receive treatment at the same time in a coordinated way, and CDC says to treat everyone who had prolonged, direct skin-to-skin contact and to offer treatment to the households of staff being treated.
- Recognize: 2 or more linked cases within 8 weeks in one setting is an outbreak (UKHSA); tell the local health protection team or health department.
- Confirm and map: skin scrapings read by a trained examiner; list rooms, roommates and hands-on staff (CDC).
- Treat together: cases and all contacts, including staff and their households, treated in one coordinated round.
- Control spread: gloves for hands-on care, hot laundry, daily cleaning and limits on transfers and admissions.
- Watch: heightened surveillance for 12 weeks after the last case's symptom onset before declaring the outbreak over (UKHSA).
Environment, staff and admissions
CDC advises machine washing and hot drying of bedding and clothing, since temperatures above 50°C (122°F) for 10 minutes kill mites and eggs; items that cannot be laundered can be sealed in a plastic bag for several days to a week. For common scabies, CDC calls environmental disinfestation neither necessary nor warranted, and mattresses generally do not need to be thrown away. UKHSA adds daily vacuuming until 3 days after the first treatment, for longer with crusted scabies. Staff who are cases or contacts can keep working but should avoid skin-to-skin contact, wearing protective equipment for hands-on care until 24 hours after starting treatment. Settings may pause admissions, transfers of cases and contacts should ideally wait until 24 hours after the first treatment, and the receiving setting must be told. UKHSA also warns that itch can persist for up to 6 weeks after successful treatment, which does not necessarily mean treatment has failed.
Treatment choice is where outbreak teams most often need a second opinion. UKHSA notes that ivermectin tablets may be an option to consider for contacts, but that this use is currently off label in the UK and the decision should be made with specialist dermatology or infectious disease services. AskMed is useful at this point because it sets the UKHSA, CDC and WHO wording side by side with links, so an infection control nurse, GP or registrar can check what each agency actually says before the team meets. Ask it whether oral ivermectin is an option for contacts in a care-home scabies outbreak and what UKHSA says about its licensing.
Ask AskMed what UKHSA and CDC advise on treating contacts in a scabies outbreak:
What complications can scabies disease cause?
The complications of scabies come mostly from bacteria entering skin damaged by burrows and scratching, and they are why WHO treats scabies as more than a skin condition. WHO explains that the mite's effects on immunity, together with scratching, inoculate the skin with bacteria, which leads to impetigo (skin sores), especially in the tropics. Impetigo can then be complicated by deeper infection such as abscesses or by serious invasive disease, including septicaemia. Streptococcus pyogenes (group A streptococcus) is the organism that links the skin to the kidneys and heart. WHO states that several studies have shown outbreaks of scabies to be a major risk factor for acute post-streptococcal glomerulonephritis, that evidence of acute kidney damage can be found in up to 10% of children with scabies in resource-poor settings, and that in many it persists for years and contributes to permanent kidney damage. The WHO road map lists severe soft tissue infection, septicaemia, kidney disease and, possibly, rheumatic heart disease.
Impetigo is common wherever scabies is: the 2015 systematic review by Romani and colleagues found it particularly common in children, with the highest prevalence, 49.0%, in Australian Aboriginal communities. In crusted scabies, CDC names sepsis as the main risk to prevent.
Is scabies linked to rheumatic heart disease?
The heart link is real enough to study but not proven. WHO says a growing body of evidence implicates impetigo caused by Streptococcus pyogenes in rheumatic fever and rheumatic heart disease, and calls scabies-associated skin infection a possible risk factor for it. The strongest single dataset is a cohort of 213,957 Auckland children aged 3 to 12 years followed for a mean of 5.1 years (Thornley and colleagues, Journal of Paediatrics and Child Health, 2018). After adjustment for confounders, a hospital diagnosis of scabies was linked to acute rheumatic fever or chronic rheumatic heart disease with a hazard ratio of 8.98; among children admitted to hospital at least once, the hazard ratio was 3.43. That is an association, not proof of cause, and the authors call for further research. Group A streptococcal throat infection is the better-known trigger of rheumatic fever, as the guide to antibiotics for strep throat explains.
How does mass drug administration control scabies?
Mass drug administration (MDA) treats everyone in a community at the same time, whether or not each person has symptoms, and WHO supports it for scabies where community prevalence is 10% or more. The reason lies in the life cycle: a first infestation can be silent for weeks while mites spread, so treating only diagnosed people and their households leaves a reservoir behind. A WHO informal consultation of experts in 2019 found convincing evidence that MDA is highly effective at that prevalence, while evidence for lower prevalence is less clear. The programmes use oral ivermectin, with a topical scabicide such as permethrin for people who cannot take it; WHO says ivermectin should not be taken in pregnancy or by children who weigh less than 15 kg. The road map adds that ivermectin cannot be safely used where loiasis is co-endemic and lists open questions, including whether a simpler regimen would work and whether moxidectin could serve. Ivermectin is on the WHO essential medicines list for scabies.
What the trials showed
- Fiji, 2015: 2,051 people in three island communities. Scabies prevalence fell by 94% with mass ivermectin, 62% with mass permethrin and 49% with standard care of cases and contacts; impetigo fell from 24.6% to 8.0% in the ivermectin community. Adverse events were mild and more common with ivermectin (15.6% vs 6.8%).
- Solomon Islands, 2015 to 2016 (AIM): 26,188 people, 99.3% of Choiseul Province, treated with ivermectin-based MDA given alongside azithromycin for trachoma. Scabies in sentinel villages fell from 18.7% to 2.3%, and clinic visits for skin sores, boils and abscesses fell by 50.9%.
- Fiji Northern Division, 2018 to 2020: MDA for a population of 131,914, delivered with lymphatic filariasis treatment. Hospital admissions for skin and soft tissue infections were 17% lower (388 vs 467 per 100,000 person-years), impetigo fell from 15.3% to 6.1%, but childhood invasive infections and post-streptococcal complications did not change.
WHO reports large-scale scabies MDA programmes in Papua New Guinea, Vanuatu, Fiji and the Solomon Islands. For public health trainees and clinicians joining a skin NTD programme, the practical questions are precise: which prevalence counts as endemic, who is excluded from ivermectin and what the road map measures. Ask AskMed which groups WHO excludes from ivermectin mass drug administration for scabies and why loiasis matters, and each point links back to the WHO document or trial it rests on.
Ask AskMed how WHO decides where scabies mass drug administration should run:
When does scabies need urgent care or public health input?
Scabies needs prompt medical attention when the skin looks infected, when thick crusting suggests crusted scabies, or when more than one person in a shared setting is affected. Anyone with an itchy rash that could be scabies should see a doctor, nurse or pharmacist, because WHO says diagnosis rests on recognizing the typical features and all household members should be treated, even without symptoms. Seek urgent care for sores that become hot, swollen, painful or pus-filled, or for fever and feeling unwell, because WHO notes that impetigo can progress to abscesses and septicaemia. Thick, crusted or scaly skin in an older, immunosuppressed or bed-bound person needs prompt assessment, since CDC calls for aggressive treatment of crusted scabies. In a care home, prison, school or hostel, two or more linked cases within 8 weeks is an outbreak under UKHSA guidance, and the local health protection team or health department should be told.
After treatment, itch that slowly fades over a few weeks is expected: WHO says it often gets worse for 1 to 2 weeks after treatment starts, and UKHSA says it can last up to 6 weeks. New burrows, spreading rash or itch beyond that point is a reason to be seen again. Ringworm is another contagious skin condition that spreads through close contact; the guide to ringworm disease covers it.
Frequently asked questions
Is scabies a disease or an infestation?
Both terms are used. WHO describes scabies as a parasitic infestation by Sarcoptes scabiei var. hominis, and since 2017 it has classed scabies and other ectoparasites as a neglected tropical disease because of its global burden and its bacterial complications.
How long can scabies mites live off the body?
WHO says scabies mites usually die after 2 to 3 days away from human skin. That is why CDC suggests sealing items that cannot be washed in a plastic bag for several days to a week, and why hot laundering above 50°C (122°F) for 10 minutes is enough to kill mites and eggs.
Why is crusted scabies so contagious?
A person with crusted scabies can carry up to two million mites and eggs, compared with 10 to 15 mites in common scabies, and sheds them in skin scales onto bedding, clothing and furniture. Because itch is often mild, it is easily missed, and CDC says unrecognized crusted scabies is frequently the source of institutional outbreaks.
Can scabies cause kidney disease?
Yes, indirectly. Skin sores infected with Streptococcus pyogenes can trigger acute post-streptococcal glomerulonephritis. WHO says evidence of acute kidney damage is found in up to 10% of children with scabies in resource-poor settings, and that in many it persists for years.
When is a scabies outbreak over?
Under UKHSA guidance, heightened surveillance should last 12 weeks after symptom onset in the last known case, and the outbreak can be declared over if no new cases are found in that time. Itch alone can persist for up to 6 weeks after successful treatment.
Where is scabies most common?
Scabies occurs in every country but is most common in hot, crowded, resource-poor tropical areas. The Global Burden of Disease 2015 analysis found the highest burden in east Asia, southeast Asia, Oceania, tropical Latin America and south Asia, with Indonesia, China, Timor-Leste, Vanuatu and Fiji the most affected countries.
Sources
- World Health Organization. Scabies. Fact sheet, 31 May 2023.
- World Health Organization. Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030. Geneva: WHO; 2021 (scabies and other ectoparasitoses, pages 39 and 149–152).
- Centers for Disease Control and Prevention. Clinical Overview of Scabies.
- Centers for Disease Control and Prevention, DPDx. Scabies (life cycle and clinical presentation). Last reviewed 6 June 2024.
- Centers for Disease Control and Prevention. Public Health Strategies for Scabies Outbreaks in Institutional Settings.
- Centers for Disease Control and Prevention. Public Health Strategies for Crusted Scabies Outbreaks in Institutional Settings.
- UK Health Security Agency. Management of scabies cases and outbreaks in communal residential settings. GOV.UK, updated 29 April 2026.
- Karimkhani C, Colombara DV, Drucker AM, et al. The global burden of scabies: a cross-sectional analysis from the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17(12):1247-1254.
- Romani L, Steer AC, Whitfeld MJ, Kaldor JM. Prevalence of scabies and impetigo worldwide: a systematic review. Lancet Infect Dis. 2015;15(8):960-967.
- Romani L, Whitfeld MJ, Koroivueta J, et al. Mass drug administration for scabies control in a population with endemic disease. N Engl J Med. 2015;373(24):2305-2313.
- Romani L, Marks M, Sokana O, et al. Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial. Lancet Infect Dis. 2019;19(5):510-518.
- Thean LJ, Romani L, Engelman D, et al. Prevention of bacterial complications of scabies using mass drug administration: a population-based, before-after trial in Fiji, 2018-2020. Lancet Reg Health West Pac. 2022;22:100433.
- Thornley S, Marshall R, Jarrett P, et al. Scabies is strongly associated with acute rheumatic fever in a cohort study of Auckland children. J Paediatr Child Health. 2018;54(6):625-632.
- Thomas C, Coates SJ, Engelman D, Chosidow O, Chang AY. Ectoparasites: Scabies. J Am Acad Dermatol. 2020;82(3):533-548.
